Sandoz raises 2026 core EBITDA margin guidance to 23.0%-23.5%

(AWP Alliance News) - Sandoz narrowed its 2026 net sales growth forecast to 5-6% at constant currencies from mid-to-high single-digit growth. Short-term biosimilar supply constraints in Europe and International markets, alongside tougher-than-expected temporary conditions in Germany, weighed on the outlook.

Core EBITDA margin guidance rose to 23-23.5%, replacing an outlook for roughly 100 basis points of expansion from 21.7% in 2025, supported by a more favorable sales mix and stronger operations. Third-quarter net sales rose 5% at constant currencies to USD 2.94 billion, with biosimilar sales up 17%.

The outlooks through 2028 and 2030 remain unchanged, including a core EBITDA margin target of 25-27% by 2030.

https://docs.publicnow.com/DFCD34EA46662D618EB17115763779D9E9B22416

Disclaimer: This news brief was created using generative artificial intelligence. Sandoz Group AG published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.